<p>紐約，2026 年 1 月 14 日（全球新聞稿）——Psyence Biomedical Ltd.（納斯達克：PBM）（“Psyence BioMed” 或 “公司”）今天宣佈其 1 股合併為 6.25 股的股份合併（反向股票拆分）的生效日期。在 2025 年 4 月 16 日舉行的特別股東會議上，股東批准了一項特別決議，授權董事會在下次年度股東大會之前的任何時間實施最多 1 股合併為 50 股的股份合併，具體的時間和合並比例由董事會自行決定。經過這一批准，公司董事會最初授權了 1 股合併為 7.97 股的合併比例，並於 2025 年 5 月 5 日實施。2025 年 12 月 4 日，董事會批准了第二次股份合併，比例為 1 股合併為 6.25 股。</p>
<p>公司的普通股預計將在 2026 年 1 月 20 日市場開盤時以合併後的基礎開始交易。合併後，公司的普通股將繼續在納斯達克資本市場以 “PBM” 符號交易，新的 CUSIP 號碼為 74449F407。</p>
<p>在合併生效時，每 6.25 股已發行和流通的公司股份將自動合併為 1 股已發行和流通的普通股。公司的未到期認股權證和其他股權工具的股份數量及行使價格也將根據各自條款按比例調整。截至 2026 年 1 月 14 日，公司已發行和流通的普通股為 6,388,604 股。合併後，公司將有 1,022,177 股已發行和流通的普通股。</p>
<p>合併過程中不會發行任何零碎股份。合併產生的任何零碎股份如果小於半股，將向下舍入到最接近的整股；如果至少為半股，則向上舍入到最接近的整股。合併對所有股東的影響是統一的，不會改變任何股東在公司的百分比權益，除了因零碎股份處理而產生的微小調整。股份合併在註冊股東層面進行。通過經紀人、銀行或其他代理人（即以 “街名” 持有）的股東被視為實益持有人，可能會根據其經紀人、銀行或代理人的程序，經歷合併在其賬户中反映的延遲。</p>
<p>Continental Stock Transfer &amp; Trust Company 作為合併的交換代理和轉讓代理。以賬面形式或通過經紀賬户持有股份的股東無需採取任何行動。實益持有人被鼓勵與其經紀人、銀行或保管人聯繫，詢問有關股份合併影響的任何問題。</p>
<p><strong>關於 Psyence BioMed</strong></p>
<p>Psyence Biomedical Ltd.（納斯達克：PBM）是少數幾家專注於迷幻藥物治療的多資產垂直整合生物製藥公司之一。它是第一家專注於開發自然來源（非合成）的裸蓋菇素和伊波加因基礎的迷幻藥物的生命科學生物技術公司，並在納斯達克上市。我們致力於解決未滿足的心理健康需求。我們承諾採用基於證據的方法，開發安全、有效且獲得 FDA 批准的自然來源迷幻治療，適用於廣泛的心理健康障礙。</p>
<p><strong>Psyence Biomedical Ltd.的聯繫信息</strong></p>
<p>電子郵件：ir@psyencebiomed.com</p>
<p>媒體諮詢：media@psyencebiomed.com</p>
<p>一般信息：info@psyencebiomed.com</p>
<p><strong>投資者聯繫：</strong></p>
<p>Michael Kydd</p>
<p>投資者關係顧問</p>
<p>michael@psyencebiomed.com</p>
<p><strong>前瞻性聲明</strong></p>
<p>本通訊包含 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”。此類聲明包括但不限於關於未來財務和運營結果、我們的計劃、目標、期望和意圖的聲明，涉及未來的運營、產品和服務；以及其他通過 “可能導致”、“預計將”、“將繼續”、“預計”、“估計”、“相信”、“打算”、“計劃”、“預測”、“展望” 或類似含義的詞語來識別的聲明。</p>
<p>本通訊中的前瞻性聲明包括關於股份合併的時間和實施、公司普通股預計開始以合併後基礎交易的時間、公司維持符合納斯達克持續上市標準的能力、股份合併的預期影響（包括對公司普通股市場價格的影響）、新 CUSIP 號碼的發行，以及對未到期認股權證和其他股權工具的調整和股份合併在經紀和其他賬户中的反映的預期時間。這些聲明基於當前的假設和期望，包括股份合併將如預期生效，以及公司將繼續滿足納斯達克的持續上市標準。這些假設可能被證明是錯誤的。不能保證公司將繼續維持符合納斯達克的持續上市要求。存在許多風險和不確定性，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的有實質性不同。</p>
<p>這些風險和不確定性包括但不限於：(i) 完成股份合併的延遲或挑戰；(ii) 公司維持納斯達克持續上市標準的能力；(iii) 合併後公司股價可能的波動；(iv) 監管、競爭和經濟環境的變化；(v) 與公司發展計劃和臨牀試驗相關的風險；以及 (vi) 與公司股份合併的公司授權相關的風險，包括可能對授權股份合併的股東決議的有效性、解釋或充分性提出質疑的索賠或訴訟的可能性。上述因素的清單並不詳盡。您應仔細考慮上述因素以及在公司於 2025 年 11 月 3 日向證券交易委員會（“SEC”）提交的最終招股説明書（文件編號：333-298285）“風險因素” 部分中描述的其他風險和不確定性。</p>
<p>這些文件識別並解決了其他重要的風險和不確定性，這些風險和不確定性可能導致實際事件和結果與前瞻性聲明中包含的內容有實質性差異。實際結果和未來事件可能與這些聲明中預期的內容有實質性差異。此通信中的內容不應被視為任何人對此處所列前瞻性聲明將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對前瞻性聲明過度依賴，這些聲明僅在作出之日有效。除法律要求外，Psyence BioMed 不打算更新這些前瞻性聲明。</p>
<p>公司不對其擬議產品的醫療、治療或健康益處做出任何聲明。美國食品和藥物管理局、加拿大衞生部或其他類似監管機構尚未評估關於迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健產品的聲明。這些產品的有效性尚未通過授權的臨牀研究確認。無法保證迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健品的使用能夠診斷、治療、治癒或預防任何疾病或狀況。需要進行嚴格的科學研究和臨牀試驗。公司的產品候選者是實驗性的，尚未獲得任何監管機構的批准用於治療任何疾病或狀況，臨牀結果（如有）可能無法代表未來結果。任何對潛在產品的質量、一致性、有效性和安全性的引用並不意味着公司在臨牀試驗中已驗證這些內容，或公司將完成這些試驗。如果公司無法獲得商業化其業務所需的批准或研究，可能會對公司的業績和運營產生重大不利影響。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

<p>Psyence Biomedical Ltd. 宣佈將於 2026 年 1 月 20 日實施 1 股換 6.25 股的反向股票拆分。這是在股東批准最高 1 股換 50 股的合併比例後進行的。該公司的普通股將在納斯達克以 “PBM” 為交易代碼，並將獲得新的 CUSIP 號碼。合併後，股份數量將從 6,388,604 股減少至 1,022,177 股。零碎股份將進行四捨五入，股東被建議聯繫他們的經紀人以獲取詳細信息。Psyence BioMed 專注於基於迷幻藥的心理健康治療</p>

<p>NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a ratio of up to 1-for-50, with the exact timing and consolidation ratio to be determined in the Board’s sole discretion. Following this approval, the Company's Board of Directors initially authorized a 1-for-7.97 consolidation ratio which was implemented Monday, May 5, 2025. On December 4, 2025, the board approved a second share consolidation at a ratio of 1-for-6.25.</p>
<div class="lb-trans"><p>紐約，2026 年 1 月 14 日（全球新聞稿）——Psyence Biomedical Ltd.（納斯達克：PBM）（“Psyence BioMed” 或 “公司”）今天宣佈其 1 股合併為 6.25 股的股份合併（反向股票拆分）的生效日期。在 2025 年 4 月 16 日舉行的特別股東會議上，股東批准了一項特別決議，授權董事會在下次年度股東大會之前的任何時間實施最多 1 股合併為 50 股的股份合併，具體的時間和合並比例由董事會自行決定。經過這一批准，公司董事會最初授權了 1 股合併為 7.97 股的合併比例，並於 2025 年 5 月 5 日實施。2025 年 12 月 4 日，董事會批准了第二次股份合併，比例為 1 股合併為 6.25 股。</p>
</div><p>The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on January 20, 2026. Following the consolidation, the Company's common shares will continue to trade under the symbol &#34;PBM&#34; on the Nasdaq Capital Market, with a new CUSIP number 74449F407.</p>
<div class="lb-trans"><p>公司的普通股預計將在 2026 年 1 月 20 日市場開盤時以合併後的基礎開始交易。合併後，公司的普通股將繼續在納斯達克資本市場以 “PBM” 符號交易，新的 CUSIP 號碼為 74449F407。</p>
</div><p>At the effective time of the consolidation, every 6.25 issued and outstanding shares of the Company will automatically be combined into one issued and outstanding common share. The number of shares and the exercise price of the Company's outstanding warrants and other equity instruments will also be adjusted proportionately in accordance with their respective terms. As of January 14, 2026, the Company had 6,388,604 common shares issued and outstanding. As a result of the consolidation, the Company will have 1,022,177 common shares issued and outstanding.</p>
<div class="lb-trans"><p>在合併生效時，每 6.25 股已發行和流通的公司股份將自動合併為 1 股已發行和流通的普通股。公司的未到期認股權證和其他股權工具的股份數量及行使價格也將根據各自條款按比例調整。截至 2026 年 1 月 14 日，公司已發行和流通的普通股為 6,388,604 股。合併後，公司將有 1,022,177 股已發行和流通的普通股。</p>
</div><p>No fractional shares will be issued in connection with the consolidation. Any fractional share resulting from the consolidation will be rounded down to the nearest whole share if the fraction is less than one-half of a share and rounded up to the nearest whole share if the fraction is at least one-half of a share. The consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company, except for minor adjustments resulting from the treatment of fractional shares. The share consolidation occurs at the registered shareholder level. Shareholders who hold their common shares through brokers, banks, or other nominees (i.e., in 'street name') are considered beneficial holders and may experience a delay in the reflection of the consolidation in their accounts, depending on the procedures of their broker, bank, or nominee.</p>
<div class="lb-trans"><p>合併過程中不會發行任何零碎股份。合併產生的任何零碎股份如果小於半股，將向下舍入到最接近的整股；如果至少為半股，則向上舍入到最接近的整股。合併對所有股東的影響是統一的，不會改變任何股東在公司的百分比權益，除了因零碎股份處理而產生的微小調整。股份合併在註冊股東層面進行。通過經紀人、銀行或其他代理人（即以 “街名” 持有）的股東被視為實益持有人，可能會根據其經紀人、銀行或代理人的程序，經歷合併在其賬户中反映的延遲。</p>
</div><p>Continental Stock Transfer &amp; Trust Company is acting as the exchange agent and transfer agent for the consolidation. Shareholders holding their shares in book-entry form or through brokerage accounts are not required to take any action. Beneficial holders are encouraged to contact their broker, bank, or custodian with any questions regarding the effect of the share consolidation.</p>
<div class="lb-trans"><p>Continental Stock Transfer &amp; Trust Company 作為合併的交換代理和轉讓代理。以賬面形式或通過經紀賬户持有股份的股東無需採取任何行動。實益持有人被鼓勵與其經紀人、銀行或保管人聯繫，詢問有關股份合併影響的任何問題。</p>
</div><p><strong>About Psyence BioMed</strong></p>
<div class="lb-trans"><p><strong>關於 Psyence BioMed</strong></p>
</div><p>Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.</p>
<div class="lb-trans"><p>Psyence Biomedical Ltd.（納斯達克：PBM）是少數幾家專注於迷幻藥物治療的多資產垂直整合生物製藥公司之一。它是第一家專注於開發自然來源（非合成）的裸蓋菇素和伊波加因基礎的迷幻藥物的生命科學生物技術公司，並在納斯達克上市。我們致力於解決未滿足的心理健康需求。我們承諾採用基於證據的方法，開發安全、有效且獲得 FDA 批准的自然來源迷幻治療，適用於廣泛的心理健康障礙。</p>
</div><p><strong>Contact Information for Psyence Biomedical Ltd.</strong></p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd.的聯繫信息</strong></p>
</div><p>Email: ir@psyencebiomed.com</p>
<div class="lb-trans"><p>電子郵件：ir@psyencebiomed.com</p>
</div><p>Media Inquiries: media@psyencebiomed.com</p>
<div class="lb-trans"><p>媒體諮詢：media@psyencebiomed.com</p>
</div><p>General Information: info@psyencebiomed.com</p>
<div class="lb-trans"><p>一般信息：info@psyencebiomed.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p>Michael Kydd</p>
<div class="lb-trans"><p>Michael Kydd</p>
</div><p>Investor Relations Advisor</p>
<div class="lb-trans"><p>投資者關係顧問</p>
</div><p>michael@psyencebiomed.com</p>
<div class="lb-trans"><p>michael@psyencebiomed.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.</p>
<div class="lb-trans"><p>本通訊包含 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”。此類聲明包括但不限於關於未來財務和運營結果、我們的計劃、目標、期望和意圖的聲明，涉及未來的運營、產品和服務；以及其他通過 “可能導致”、“預計將”、“將繼續”、“預計”、“估計”、“相信”、“打算”、“計劃”、“預測”、“展望” 或類似含義的詞語來識別的聲明。</p>
</div><p>Forward-looking statements in this communication include statements regarding the timing and implementation of the share consolidation, the expected timing for the Company’s common shares to begin trading on a post-consolidated basis, the Company’s ability to maintain compliance with Nasdaq’s continued listing standards, the anticipated effects of the share consolidation (including on the market price of the Company’s common shares), the issuance of a new CUSIP number, and the expected timing of adjustments to outstanding warrants and other equity instruments and the reflection of the share consolidation in brokerage and other accounts. These statements are based on current assumptions and expectations, including that the share consolidation will become effective as anticipated, and that the Company will continue to meet Nasdaq’s ongoing listing standards. These assumptions may prove incorrect. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本通訊中的前瞻性聲明包括關於股份合併的時間和實施、公司普通股預計開始以合併後基礎交易的時間、公司維持符合納斯達克持續上市標準的能力、股份合併的預期影響（包括對公司普通股市場價格的影響）、新 CUSIP 號碼的發行，以及對未到期認股權證和其他股權工具的調整和股份合併在經紀和其他賬户中的反映的預期時間。這些聲明基於當前的假設和期望，包括股份合併將如預期生效，以及公司將繼續滿足納斯達克的持續上市標準。這些假設可能被證明是錯誤的。不能保證公司將繼續維持符合納斯達克的持續上市要求。存在許多風險和不確定性，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的有實質性不同。</p>
</div><p>These risks and uncertainties include, among others: (i) delays or challenges in completing the share consolidation; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price following the consolidation; (iv) changes in the regulatory, competitive, and economic landscape; (v) risks associated with the Company’s development plans and clinical trials; and (vi) risks related to the Company’s corporate authorizations for the share consolidation, including the possibility of claims or proceedings challenging the validity, interpretation or sufficiency of the shareholder resolutions authorizing the share consolidation. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.</p>
<div class="lb-trans"><p>這些風險和不確定性包括但不限於：(i) 完成股份合併的延遲或挑戰；(ii) 公司維持納斯達克持續上市標準的能力；(iii) 合併後公司股價可能的波動；(iv) 監管、競爭和經濟環境的變化；(v) 與公司發展計劃和臨牀試驗相關的風險；以及 (vi) 與公司股份合併的公司授權相關的風險，包括可能對授權股份合併的股東決議的有效性、解釋或充分性提出質疑的索賠或訴訟的可能性。上述因素的清單並不詳盡。您應仔細考慮上述因素以及在公司於 2025 年 11 月 3 日向證券交易委員會（“SEC”）提交的最終招股説明書（文件編號：333-298285）“風險因素” 部分中描述的其他風險和不確定性。</p>
</div><p>These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.</p>
<div class="lb-trans"><p>這些文件識別並解決了其他重要的風險和不確定性，這些風險和不確定性可能導致實際事件和結果與前瞻性聲明中包含的內容有實質性差異。實際結果和未來事件可能與這些聲明中預期的內容有實質性差異。此通信中的內容不應被視為任何人對此處所列前瞻性聲明將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對前瞻性聲明過度依賴，這些聲明僅在作出之日有效。除法律要求外，Psyence BioMed 不打算更新這些前瞻性聲明。</p>
</div><p>The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司不對其擬議產品的醫療、治療或健康益處做出任何聲明。美國食品和藥物管理局、加拿大衞生部或其他類似監管機構尚未評估關於迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健產品的聲明。這些產品的有效性尚未通過授權的臨牀研究確認。無法保證迷幻蘑菇、迷幻蘑菇類似物或其他迷幻化合物或營養保健品的使用能夠診斷、治療、治癒或預防任何疾病或狀況。需要進行嚴格的科學研究和臨牀試驗。公司的產品候選者是實驗性的，尚未獲得任何監管機構的批准用於治療任何疾病或狀況，臨牀結果（如有）可能無法代表未來結果。任何對潛在產品的質量、一致性、有效性和安全性的引用並不意味着公司在臨牀試驗中已驗證這些內容，或公司將完成這些試驗。如果公司無法獲得商業化其業務所需的批准或研究，可能會對公司的業績和運營產生重大不利影響。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNTgxNCM3MzYxNjg2IzIyODU5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

Psyence BioMed 宣佈 1 比 6.25 反向股票拆分的生效日期 | PBM 股票新聞